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Abstract
Genetic mutations in FUS, a DNA/RNA-binding protein, are associated with inherited 
forms of frontotemporal lobar degeneration (FTLD) and amyotrophic lateral sclerosis 
(ALS). A novel transgenic FUS[1-359]-tg mouse line recapitulates core hallmarks of 
human ALS in the spinal cord, including neuroinflammation and neurodegeneration, 
ensuing muscle atrophy and paralysis, as well as brain pathomorphological signs of 
FTLD. However, a question whether FUS[1-359]-tg mouse displays behavioural and 
brain pro-inflammatory changes characteristic for the FTLD syndrome was not ad-
dressed. Here, we studied emotional, social and cognitive behaviours, brain markers 
of inflammation and plasticity of pre-symptomatic FUS[1-359]-tg male mice, a po-
tential FTLD model. These animals displayed aberrant behaviours and altered brain 
expression of inflammatory markers and related pathways that are reminiscent to 
the FTLD-like syndrome. FTLD-related behavioural and molecular Journal of Cellular 
and Molecular Medicine features were studied in the pre-symptomatic FUS[1-359]-tg 
mice that received standard or new ALS treatments, which have been reported to 
counteract the ALS-like syndrome in the mutants. We used anti-ALS drug riluzole 
(8 mg/kg/d), or anti-inflammatory drug, a selective blocker of cyclooxygenase-2 
(celecoxib, 30 mg/kg/d) for 3 weeks, or a single intracerebroventricular (i.c.v.) infusion 
of human stem cells (Neuro-Cells, 500 000-CD34+), which showed anti-inflammatory 
properties. Signs of elevated anxiety, depressive-like behaviour, cognitive deficits and 
abnormal social behaviour were less marked in FUS-tg–treated animals. Applied treat-
ments have normalized protein expression of interleukin-1β (IL-1β) in the prefrontal 
cortex and the hippocampus, and of Iba-1 and GSK-3β in the hippocampus. Thus, the 
pre-symptomatic FUS[1-359]-tg mice demonstrate FTLD-like abnormalities that are 
attenuated by standard and new ALS treatments, including Neuro-Cell preparation.
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1  | INTRODUC TION
Genetic mutations in FUS, which is DNA/RNA-binding protein, can 
cause frontotemporal lobar degeneration (FTLD) and amyotrophic 
lateral sclerosis (ALS).1 FTLD is a debilitating disease, often accom-
panying ALS and involving atrophy of the frontal/temporal lobes and 
affecting emotional, social and cognitive functions.2 Until recently, 
the contribution of FUS to the FTLD/ALS pathology remains poorly 
understood. The available FTLD models based on the FUS mutation 
often report somewhat non-specific behavioural deficits and limited 
brain pathology with a late onset,3 or the very rapid development of 
physiological and motor ALS-like pathology4, and, for this reason, 
it has been argued that further refinement is required.5 The con-
struction of the FUS[1-359]-tg mice, expressing truncated human 
FUS[1-359], has been shown to exhibit many of the hallmark charac-
teristics of ALS,6 and FTDL-like changes during the pre-symptomatic 
stage.7 This model provides a promising tool to explore the temporal 
contribution of FUS mutations on molecular and behavioural out-
come. Meanwhile, hitherto the FTDL-like behavioural features and 
the accompanying molecular changes have not been investigated. 
Here were addressed this outstanding issue by studying the impact 
of therapy used in the clinic and new anti-inflammatory therapies 
on emotional, cognitive and social abnormalities in FUS-tg animals. 
These therapies have been shown to reduce the ALS-like pathology 
in these mutants.8
2  | METHODOLOGY
Animals, study design, methodology and statistical analysis are de-
scribed in a Appendix S1 (see also Figure S1). At the age of eight 
weeks, which is considered to be the beginning of adulthood, the 
FUS[1-359]-tg (FUS-tg) male mutants display no signs of neurode-
generation in the CNS (Figure S3), nor any motor deficits.6,8 For this 
reason we selected mice of this age for both Study 1 and Study 2. 
FUS-tg mice used here showed no deficits in motor tests (not shown). 
Over the course of 5 days, wild-type (WT) and FUS-tg mice of aver-
age age of 9 weeks were investigated for (a) time spent in the open 
arms of the O-maze, (b) sucrose preference, (c) the duration of im-
mobility in the tail suspension test, (d) number of rears in the novel 
cage test, (e) displacement of pellets in the marble test, and (f) the 
duration of attacks and tail rattling in the resident-intruder test.9 The 
FTLD syndrome is well documented to be associated with patho-
logical changes in the limbic system, including the hippocampus and 
prefrontal cortex and underlie emotional, social and cognitive abnor-
malities.5 These two structures play pivotal roles in the regulation of 
social, anxiety- and depressive-like behaviours, as well as explora-
tion and cognitive tasks in the mouse models employed here 9 and, 
hence, were studied for potential molecular changes (Figure S1A). 
Therefore, mice were killed and the hippocampus and the prefron-
tal cortex collected for RNA isolation/cDNA synthesis and RT-PCR 
assay of FTDL-related pro-inflammatory markers: tumour necrosis 
factor (TNF), cyclooxygenase-1 (COX-1), interleukin-1β (IL-1β) and 
cytokine expression regulatory molecules implicated in the ALS 
pathology, matrix-metalloproteinase-9 (MMP-9) and tissue inhibi-
tor of metalloproteinase-1 (TIMP-1).2 For experimental details, see 
Appendix S1 and Table S1).
Then, per os administration of the commonly used ALS treatment 
riluzole (8 mg/kg/d), oranti-inflammatorycyclooxygenase-2 blocker 
celecoxib (30 mg/kg/d), or vehicle, to FUS-tg and WT mice of aver-
age age of 9 weeks was started; or they received an intracerebroven-
tricular (i.c.v.) infusion of Neuro-Cells (1.39 × 106 mesenchymal and 
haemopoietic human stem cellscontaining 5 × 105 of CD34+ cells) 
or Ringer-solution,8,10 for details on Neuro-Cells preparation, see 
Appendix S1 and Tables S3 and S4). Two weeks later, over a period 
of 5 days, mice were behaviourally scored for (a) time spent in lit box 
in the dark/light test, (b) new object recognition index, (c) the dura-
tion of immobility in the tail suspension test, and (d) duration of fol-
lowing, number of attacks and of tail rattling in the resident-intruder 
test.11 A different battery of tests was employed in the second set 
of animals with the aim of providing an extended behavioural char-
acterization of new FUS-tg line (Figure S1B). To compare molecular 
changes of mutants in brains to the reported changes in the spinal 
cord, mice were killed at age of 15 weeks, and the hippocampus and 
the prefrontal cortex were dissected for Western blots for IL-1β, Iba-
1, glycogen-synthase-kinase-3 (GSK-3)-β and GSK-3α.8,10 For exper-
imental details, see Appendix S1 and Table S2).
Data were treated by unpaired two-tailed t test, or one- or two-
way ANOVA followed by Tukey's test, for two or multiple group 
comparisons, respectively. Repeated measures were analysed by 
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F I G U R E  1   FTLD-like changes in FUS-tg mice in (A-G) behavioural parameters and (H-O) molecular markers; *P < .05: FUS-tg (n = 9-15) vs 
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two-way ANOVA for repeated measures followed by Sidak post hoc 
test.
3  | RESULTS AND DISCUSSION
For full statistical results, see Supplementary Tables.
3.1 | Pre-symptomatic FUS-tg mice display aberrant 
behaviours and pro-inflammatory changes
FUS-tg mice spent less time in open arms of the elevated O-maze 
and exhibited a reduced latency to immobility in the tail suspension 
test, decreased sucrose preference, reduced duration of attacks 
(P < .05 vs controls, unpaired t test; Figure 1A-D), and the duration 
of tail rattling was unchanged (P > .5; Figure 1E; Table S5A). A lack 
of group differences in general locomotion in the O-maze rules out 
a possibility of non-specific confounds in behavioural analysis of 
two genotypes (Figure S3). Two-way ANOVA for repeated meas-
ures revealed significant time x genotype interaction and genotype 
effect in the number of rears in the novel cage test (P < .05; Table 
S5B). Sidak post hoc test for multiple comparisons showed signifi-
cant increase of this measure in FUS-tg mice on the 4th min (P < .05 
vs WT mice; Figure 1F) and trends to such changes on minutes 2, 
3 and 5 (P > .05, Table S5B). In comparison with controls, mutants 
exhibited unchanged activity on the 1st min of scoring (P > .5, t 
test; Table S5C) and significantly higher number of rearings aver-
aged over the 2nd-5th min of the test (P < .05, t test), thus, showing 
disrupted novelty adaptation (Figure 1F).
There were significant time and genotype effects, as well as 
significant time x genotype interaction the in number of pellets 
displaced during the marble test (P < .05, two-way ANOVA for re-
peated measures; Table S5D). FUS-tg mice displaced fewer pellets 
during all time periods of the test, except for 0-15 minutes, suggest-
ing deficient hippocampus-dependent performance (P < .05 vs WT 
mice, Sidak post hoc test; Figure 1G; Table S5D).
Signs of helplessness, anhedonia, anxiety-like features, cogni-
tive and social abnormalities in FUS-tg animals are characteristic 
of other FTDL paradigms, that is progranulin-deficient mice,12 
ΔNLS-FUS mice3 and TDP-43-tg mice.13 The current study sug-
gests the most prominent FDTL-related deficits of the FUS-tg 
mice are the classic tests of emotionality, social and hippocam-
pus-dependent performance. In comparison with other FTLD ro-
dent models based on the FUS mutation, the findings reported 
here in the FUS-tg mice suggest that no hyperactivity or other 
non-specific behavioural alternations are present, but, typical for 
this disease, features of anxiety, apathy, cognitive and social defi-
cits are observed.3,5,7 Hippocampal concentrations of TNF and 
COX-1 mRNA were elevated in the FUS-tg mice (P < .05 vs con-
trols; unpaired t test; Figure 1H-M, Table S6). The Timp1/Mmp9 
ratio was augmented in the prefrontal cortex (P < .05, t test; 
Figure 1J-K), and no other group differences were present (P > .5, 
t test). Together, these data provide evidence of pro-inflammatory 
changes within the brain of the FUS-tg mice that a characteristic 
for FTDL-syndrome14 and aberrant Timp1/Mmp9 ratio, a factor of 
ALS pathology,2 cytokine expression15 and neuronalplasticity.16,17
3.2 | Ameliorative effects of standard ALS 
treatments and ‘Neuro-cells’ on the behavioural and 
molecular changes in the FUS-tg mice
Concerning the duration of immobility, there were no significant ef-
fects of genotype, treatment, or their interaction (P > .5, two-way 
ANOVA, Table S7), but FUS-tg-Veh displayed elevated immobil-
ity scores (P < .05, vs WT-Veh group, Tukey's test; Figure 2A), that 
were not observed in the treated mutants (P > .05, Tukey's test). In 
comparison with FUS-tg-Veh mice, this behaviour was decreased in 
FUS-tg-NC, but not FUS-tg-Ril and FUS-tg-Cel animals (P < .05 and 
P > .5, respectively; Tukey's test). For the time spent in the lit box, 
there were no significant effects of treatment, a genotype x treat-
ment interaction (P > .5, two-way ANOVA), but there was an impact 
of genotype (P < .05, two-way ANOVA). In comparison with respec-
tive wild-type controls, FUS-tg-Veh animals, but not treated mutants 
exhibited a shortened duration of time spent in the lit box (P < .05 
and P > .5, respectively, Tukey's test; Figure 2B, Table S7), which 
was increased in FUS-tg-NC vs FUS-tg-Veh animals (P < .05, Tukey's 
test). No other group differences were found.
There were no group differences in the object exploration (P > .5, 
two-way ANOVA and Tukey's test; not shown). A significant genotype 
x treatment interaction and effects of genotype (P < .05, two-way 
ANOVA), not of treatment (P > .5, two-way ANOVA), were found for 
the preference for the new object. All mutants except FUS-tg-NC 
animals had decreased scores for this measure (P < .05 and P > .05, 
vs WT groups, respectively, Tukey's test; Figure 2D, Table S7). A sig-
nificant genotype x treatment interaction was revealed for the dura-
tion of ‘following’ (P < .05 and P > .5, respectively, two-way ANOVA), 
but not for numbers of attacks and tail rattling (P > .5, Tukey's test; 
Figure 2E,F, Table S7). There was a significant genotype effect on the 
duration of following and number of attacks, but no significant treat-
ment group differences (P > .05, two-way ANOVA). We found a signif-
icant treatment effect on the duration of following (P < .05, two-way 
ANOVA), which was increased in FUS-tg-Veh and FUS-tg-Cel mice 
(P < .05, Tukey's test vs respective control groups; Figure 2D, Table 
S7), and FUS-tg-Cel group showed its decrease vs FUS-tg-Veh group 
(P < .05, Tukey's test). No other group differences were found. Thus, 
treatments ameliorated the behavioural end-points in the FUS-tg mice, 
where their effects on the measures of anxiety and aggression were 
particularly profound, suggesting their importance in the evaluation of 
FDTL-like features in this mouse line.
Hippocampal concentrations of IL-1β, Iba-1, GSK-3β and 
GSK-3α were different between the groups (P < .05; one-way 
ANOVA, Figure 2G-J, Figure S4A; Table S8A). FUS-tg-Veh animals 
exhibited increased expression of all molecules except GSK-3α 
(P < .05 and P > .05, vs WT-Veh; respectively; Tukey's test). In 
     |  10255de MUNTeR eT al.
FUS-tg-NC mice, concentrations of IL-1β and GSK-3βwere lower 
than in the FUS-tg-Veh group (P < .05, Tukey's test). In the pre-
frontal cortex, levels of IL-1β, Iba-1 and GSK-3β were different be-
tween the groups (P < .05), but not for GSK-3α (P > .05 and P > .05, 
respectively, Tukey's test). FUS-tg-Veh animals displayed elevated 
expression of the target molecules (P < .05, vs WT-Veh), except 
GSK-3α (P > .05, Tukey's test; Figure 2K-N, Figure S4B, Table S8B). 
Concentrations of IL-1βwere found to be decreased in FUS-tg-NC 
vs FUS-tg-Veh mice (P < .05, Tukey's test). No other group differ-
ences were found. In summary, FUS-tg mutants displayed up-reg-
ulated protein expression for the inflammatory markers and for 
GSK-3, which was reminiscent of the changes observed in the spi-
nal cord4 and were sensitive to the treatments. Thus, behavioural 
and molecular abnormalities of FUS-tg mice were overly reduced 
by the use of Rilusole, celecoxib or Neuro-Cells, which often ex-
erted greater effects.
F I G U R E  2   Ameliorative effects of standard ALS treatments and Neuro-Cells in FUS-tg mice on (A-F) behaviours and (G-N) expression 
of FTLD/ALS-related molecular markers;*P < .05, vs respective WT-group (n = 6-12), #P < .05, vs FUS-tg-Veh group (n = 7-14); ANOVA and 
Tukey's test (see the text)
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4  | CONCLUSIONS
Together, the pre-symptomatic FUS[1-359]-tg mice demonstrate be-
havioural changes that are reminiscent of the FTLD-syndrome ab-
normalities, and they are attenuated by all the treatments. Hence, 
FUS[1-359]-tg mutant mice can be exploited as a new paradigm of 
the FTLD to address molecular mechanisms underlying this disease 
and test new treatment options.
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